ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR
The phase 3 ARES trial of MaaT013 in third-line GI-aGVHD met its primary end point of GI-ORR at day 28.
Related Articles
GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma
The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.
First-Line Belzutifan/Cabozantinib Delivers Responses and Manageable Toxicities in ccRCC
Frontline belzutifan plus cabozantinib elicited durable responses and was tolerable in patients with treatment-naive advanced ccRCC.
Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas – PubMed
Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification of RCC is primarily based on…
Multidisciplinary Collaboration Is Crucial in Managing Ocular Toxicities of Mirvetuximab Soravtansine in Gynecologic Tumors
Rebecca Arend, MD, and Kathryn Lyle, CRNP, discuss their approach to managing ocular and other treatment-related toxicities associated with mirvetuximab soravtansine.
Cervical Cancer: Facts, Symptoms, Treatment | OSUCCC – James
Cervical cancer is a rare form of gynecologic cancer. Learn about cervical cancer signs, symptoms, causes and treatments from the OSUCCC – James.
Advancing Cell Therapy Research, Discovery & Innovation : Oncology Times
An abstract is unavailable.
ctDNA Testing Joins NCCN Guidelines for MRD Assessment in DLBCL
The NCCN Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment.
Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC
Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Registration | Society of Gynecologic Oncology
The SGO Winter Meeting connects researchers and surgeons at all career stages through scientific sessions, bold discussions, posters, and networking events, while offering winter and…
